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POGLUT1, the putative effector 
gene driven by rs2293370 in primary 
biliary cholangitis susceptibility 
locus chromosome 3q13.33
Yuki Hitomi  1, Kazuko Ueno2,3, Yosuke Kawai1, Nao Nishida4, Kaname Kojima2,3, 
Minae Kawashima5, Yoshihiro Aiba6, Hitomi Nakamura6, Hiroshi Kouno7, Hirotaka Kouno7, 
Hajime Ohta7, Kazuhiro Sugi7, Toshiki Nikami7, Tsutomu Yamashita7, Shinji Katsushima  7, 
Toshiki Komeda7, Keisuke Ario7, Atsushi Naganuma7, Masaaki Shimada7, Noboru Hirashima7, 
Kaname Yoshizawa7, Fujio Makita7, Kiyoshi Furuta7, Masahiro Kikuchi7, Noriaki Naeshiro7, 
Hironao Takahashi7, Yutaka Mano7, Haruhiro Yamashita7, Kouki Matsushita7, Seiji Tsunematsu7, 
Iwao Yabuuchi7, Hideo Nishimura7, Yusuke Shimada7, Kazuhiko Yamauchi7, Tatsuji Komatsu7, 
Rie Sugimoto7, Hironori Sakai7, Eiji Mita7, Masaharu Koda7, Yoko Nakamura7, 
Hiroshi Kamitsukasa7, Takeaki Sato7, Makoto Nakamuta7, Naohiko Masaki  7, 
Hajime Takikawa8, Atsushi Tanaka  8, Hiromasa Ohira9, Mikio Zeniya10, Masanori Abe11, 
Shuichi Kaneko12, Masao Honda12, Kuniaki Arai12, Teruko Arinaga-Hino13, Etsuko Hashimoto14, 
Makiko Taniai14, Takeji Umemura  15, Satoru Joshita  15, Kazuhiko Nakao16, 
Tatsuki Ichikawa16, Hidetaka Shibata16, Akinobu Takaki17, Satoshi Yamagiwa18, 
Masataka Seike19, Shotaro Sakisaka20, Yasuaki Takeyama  20, Masaru Harada21, Michio Senju21, 
Osamu Yokosuka22, Tatsuo Kanda  22, Yoshiyuki Ueno  23, Hirotoshi Ebinuma24, 
Takashi Himoto25, Kazumoto Murata4, Shinji Shimoda26, Shinya Nagaoka6, Seigo Abiru6, 
Atsumasa Komori6,27, Kiyoshi Migita6,27, Masahiro Ito6,27, Hiroshi Yatsuhashi6,27, 
Yoshihiko Maehara28, Shinji Uemoto29, Norihiro Kokudo30, Masao Nagasaki2,3,31, 
Katsushi Tokunaga1 & Minoru Nakamura6,7,27,32
Primary biliary cholangitis (PBC) is a chronic and cholestatic autoimmune liver disease caused by the 
destruction of intrahepatic small bile ducts. Our previous genome-wide association study (GWAS) 
identified six susceptibility loci for PBC. Here, in order to further elucidate the genetic architecture of PBC, 
a GWAS was performed on an additional independent sample set, then a genome-wide meta-analysis 
with our previous GWAS was performed based on a whole-genome single nucleotide polymorphism (SNP) 
imputation analysis of a total of 4,045 Japanese individuals (2,060 cases and 1,985 healthy controls). A 
susceptibility locus on chromosome 3q13.33 (including ARHGAP31, TMEM39A, POGLUT1, TIMMDC1, and 
CD80) was previously identified both in the European and Chinese populations and was replicated in the 
Japanese population (OR = 0.7241, P = 3.5 × 10−9). Subsequent in silico and in vitro functional analyses 
identified rs2293370, previously reported as the top-hit SNP in this locus in the European population, as 
the primary functional SNP. Moreover, e-QTL analysis indicated that the effector gene of rs2293370 was 
Protein O-Glucosyltransferase 1 (POGLUT1) (P = 3.4 × 10−8). This is the first study to demonstrate that 
POGLUT1 and not CD80 is the effector gene regulated by the primary functional SNP rs2293370, and that 
increased expression of POGLUT1 might be involved in the pathogenesis of PBC.
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Primary biliary cholangitis (PBC) is a chronic and progressive cholestatic liver disease characterized by chronic 
non-suppurative destructive cholangitis (CNSDC), ductopenia, interface hepatitis, fibrosis, and biliary cirrho-
sis1,2. The destruction of small bile ducts is considered to be mediated by autoimmune responses against biliary 
epithelial cells (BEC), including CD4+ T cells, CD8+ T cells, B cells, and natural killer (NK) cells2–4. The higher 
monozygotic/dizygotic (MZ/DZ) ratio and the higher estimated relative sibling risk (λs) in PBC patients as com-
pared to unaffected individuals indicates the involvement of strong genetic factors in the development of PBC5,6. 
Previous genome-wide association studies (GWASs), ImmunoChip analyses, and subsequent meta-analyses 
in populations of European descent identified human leukocyte antigen (HLA) and 30 non-HLA suscep-
tibility regions (nearest candidate genes from the top-hit SNPs in each locus: IL12RB2/DENND1B/C11orf53, 
YPEL5/LBH ,  IL1RL1/IL1RL2 ,  STAT4/NAB1 ,  SLC19A3/CCL20 ,  PLCL2 ,  TIMMDC1/TMEM39A , 
IL-12A/IL12A-AS1/IQCJ/SCHIP1, DGKQ, NFKB1/MANBA, IL7R/CAPSL, NUDT12/C5orf30, IL12B, 
OLIG3/TNFAIP3, ELMO1, IRF5/TNPO3, RPS6KA4, DDX6/CXCR5, TNFRSF1A, ATXN2/BRAP, DLEU1/BCMS, 
RAD51B, EXOC3L4, RMI2/CLEC16A, IRF8/FOXF1, ZPBP2/GSDMB/IKZF3, MAPT, TYK2, SPIB, and 
SYNGR1/PDGFB/RPL3) in PBC7–14. Additionally, Asian-specific susceptibility regions for PBC, including CD58, 
CD28/CTLA4, IL21-AS1, TNFSF15/TNFSF8, IL16, IL21R, CSNK2N2/CCDC113, and AATID3A, were reported 
in the Japanese and Chinese populations by means of GWAS and subsequent genome-wide meta-analysis with 
genome-wide SNP imputation (already identified PBC susceptibility loci including this study are shown in 
Table 1)15–17. Thus, the evidence reported to date indicates presence of shared and non-shared genetic susceptibil-
ity profiles behind the pathogenesis of PBC in European and Asian populations.
Thousands of genetic variations associated with susceptibility to human complex diseases have been identi-
fied by GWASs18. Among genes located near the “top-hit SNP” in each susceptibility locus, candidate genes with 
well-known functions are often selected as the “disease susceptibility genes”. The majority of SNPs that regulate 
gene expression are actually found in the vicinity of genes within 100 kb of the transcription start site (TSS)19. 
However, trans-acting expression quantitative trait loci (e-QTL) variations, whose target transcripts are separated 
by arbitrary distances, are believed to explain a substantial proportion of the heritable variation in gene expres-
sion20. For example, although FTO was reported as a susceptibility gene for obesity, the effector genes whose 
expression levels were influenced by the significantly associated SNPs were not FTO but Iroquois Homeobox 3 
(IRX3) and IRX521. In PBC, a locus on chromosome 17q12-21 (ORMDL3-GSDMB-ZPBP2-IKZF3) has been 
reported as a shared susceptibility locus in different populations. Although the top-hit SNP was located in the 
IKAROS family zinc finger 3 (IKZF3), in which the function of the protein product is related to the proliferation 
and differentiation of B cells, the effector gene in this locus was identified as ORMDL sphingolipid biosynthesis reg-
ulator 3 (ORMDL3), whose protein product regulates endoplasmic reticulum (ER)-mediated Ca2+ homeostasis 
and facilitates the unfolded-protein response (UPR)22,23. Therefore, understanding the contribution of suscepti-
bility loci to the onset of diseases requires identification of the effector genes that are regulated by the primary 
functional variation located in the disease susceptibility loci.
The present study aimed to further elucidate the genetic architecture of PBC in the Japanese population. 
To this end, we performed a GWAS and subsequent genome-wide meta-analysis based on a whole-genome 
SNP imputation analysis with previous GWAS16. The PBC susceptibility locus chromosome 3q13.33 (including 
ARHGAP31, TMEM39A, POGLUT1, TIMMDC1, and CD80) has been identified by GWAS as a PBC susceptibility 
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locus in European and Chinese populations; consequently, this genome-wide meta-analysis involved replicating 
chromosome 3q13.33 in the Japanese population. Here, we show in silico and in vitro functional analyses and 
identify the effector gene and the primary functional SNP in the PBC susceptibility locus chromosome 3q13.33.
Chromosome Location Mapped gene(s) Top-hit SNP MAFa ORb P Population Ref.
1 1p13.1 CD58 rs2300747 0.39 1.29 2.E-12 Chinese 17
1p31.3 IL12RB2/DENND1B/C1orf53 rs72678531 0.16 1.61 2.E-38 European 12
2 2p23.1 YPEL5/LBH rs4952108 0.19 1.28 5.E-08 European 14
2q12.1 IL1RL1/IL1RL2 rs12712133 0.44 1.14 5.E-09 European 14
2q32.2 STAT4/NAB1 rs3024921, etc. 0.05 0.72 9.E-25 European 12
rs10168266 0.32 1.31 4.E-14 Chinese 17
2q33.2 CD28/CTLA4 rs4675369 0.42 1.31 1.E-13 Chinese 17
2q36.3 SLC19A3/CCL20 rs4973341 0.33 1.22 2.E-10 European 14
3 3p24.3 PLCL2 rs1372072 0.37 1.20 2.E-08 European 10
3q13.33 TIMMDC1/TMEM39A rs2293370 0.16 1.39 7.E-16 European 12
rs3732421 0.34 1.35 3.E-13 Chinese 17
rs57271503 0.34 0.72 3.E-09 Japanese This study
3q25.33 IL-12A/IL12A-AS1/IQCJ/SCHIP1 rs2366643, etc. 0.38 0.62 3.E-35 European 12
rs582537 0.29 1.33 2.E-11 Chinese 17
4 4p16.3 DGKQ rs11724804 0.44 1.22 9.E-12 European 14
4q24 NFKB1/MANBA rs7665090 0.49 1.26 8.E-14 European 12
rs1598856 0.49 1.26 2.E-10 Chinese 17
rs17033015 0.47 1.35 9.E-10 Japanese This study
4q27 IL21-AS1 rs925550 0.35 1.31 4.E-13 Chinese 17
5 5p13.2 IL7R/CAPSL rs6871748 0.28 1.30 2.E-13 European 12
rs12697352 0.19 0.68 2.E-09 Japanese This study
5q21.1 NUDT12/C5orf30 rs526231 0.32 1.15 1.E-08 European 14
5q33.3 IL12B rs2546890 0.50 1.15 1E-10 European 14
6 6q23.3 OLIG3/TNFAIP3 rs6933404 0.17 1.18 1E-10 European 14
7 7p14.1 ELMO1 rs6974491 0.16 1.25 4.E-08 European 10
7q32.1 IRF5/TNPO3 rs10488631 0.10 1.59 5.E-23 European 14
9 9q32 TNFSF15/TNFSF8 rs4979467 0.37 1.53 1.E-29 Chinese 17
rs4979462 0.32 0.60 2.E-26 Japanese This study
11 11q13.1 RPS6KA4 rs538147 0.39 1.23 2.E-10 European 10
11q23.3 DDX6/CXCR5 rs80065107 0.19 1.39 7.E-16 European 12
rs77871618 0.16 1.40 3.E-13 Chinese 17
12 12p13.31 TNFRSF1A rs1800693 0.43 0.74 7.E-19 European 12
rs4149576 0.14 1.37 4.E-09 Chinese 17
12q24.12 ATXN2/BRAP rs11065987 0.37 1.19 3.E-08 European 14
13 13q14.2 DLEU1/BCMS rs9591325 0.05 1.63 1.E-10 European 14
14 14q24.1 RAD51B rs911263 0.33 1.29 2.E-11 European 10
14q32.32 EXOC3L4 rs2297067 0.22 1.39 6.E-19 European 14
15 15q25.1 IL16 rs11556218 0.19 1.29 9.E-09 Chinese 17
16 16p12.1 IL21R rs2189521 0.30 1.41 4.E-16 Chinese 17
16p13.13 RMI2/CLEC16A rs1646019, etc. 0.30 1.38 2.E-23 European 12
16q21 CSNK2N2/CCDC113 rs2550374 0.48 1.23 2.E-08 Chinese 17
16q24.1 IRF8/FOXF1 rs11117432 0.23 1.31 5.E-11 European 10
17 17q21.1 ZPBP2/GSDMB/IKZF3 rs8067378 0.47 1.26 6.E-14 European 12
rs9635726 0.41 1.37 2.E-16 Chinese 17
rs4795395 0.35 1.42 4.E-12 Japanese This study
17q21.31 MAPT rs17564829 0.23 1.25 2.E-09 European 12
19 19p13.2 TYK2 rs34536443 0.03 1.95 1.E-12 European 12
19p13.3 ARID3A rs10415976 0.47 1.30 4.E-12 Chinese 17
19q13.33 SPIB rs3745516 0.21 1.39 1.E-20 European 14
22 22q13.1 SYNGR1/PDGFB/RPL3 rs2267407 0.24 1.29 1.E-13 European 12
rs137603 0.13 1.37 3.E-08 Chinese 17
Table 1. Non-HLA PBC susceptibility loci in European, Chinese, and Japanese populations. aMAF (minor 
allele frequency) in 1000 genome project in each population. bOR (odds ratio).
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Results
GWAS and genome-wide meta-analysis. We genotyped an independent set of 1,148 samples (668 PBC 
cases and 480 healthy controls) using the Affymetrix Japonica V1 Array24. Thirty-four samples were excluded by 
Dish QC (<0.82) or overall call rate for a total of 20,000 SNPs (<0.97) and 13 samples were excluded because 
of cryptic relatives. A further 13 samples were located far from the JPT cluster drawn using the first and second 
components after PCA and were removed from further analysis (Supplementary Fig. 1A). We re-genotype called 
about 2,897 samples (1,392 PBC cases and 1,505 healthy controls) collected in the previous study16. Eighteen 
samples were excluded by Dish QC (<0.82) or overall call rate for a total of 20,000 SNPs (<0.97) and 15 samples 
were excluded because of cryptic relatives. Seventeen samples were located far from the HapMap JPT cluster 
drawn using the first and second components after PCA and were removed from further analysis (Supplementary 
Fig. 1B).
A quantile-quantile plot of the distribution of test statistics for the comparison of allele frequencies in the 
PBC cases and healthy controls provided an inflation factor lambda value of 1.097 for all tested SNPs for the 
1,148 entries in the current dataset and a value 1.061 for the 2,897 entries in the previous dataset (Supplementary 
Fig. 2). Genotype imputation and the association study were separately performed for the two datasets. The pro-
cess of data cleaning and meta-analysis is summarized in Supplementary Fig. 3.
Figure 1 shows a genome-wide view of the single-point association data based on allele frequencies after 
meta-analysis. The loci HLA, TNFSF15, IL7R, NFKB1/MANBA, and chromosome 17q12-21 showed significant 
associations with PBC, as reported in the previous GWAS performed on a Japanese population16. In addition to 
these regions, meta-analysis to combine the two datasets showed a significant association in chromosome 3q13.33 
(Top hit SNP: rs57271503, OR = 0.7241, P = 3.5 × 10−9, Fig. 2), although this locus appears as evidence of no asso-
ciation with PBC from studies using each platform (Japonica and ASI, Supplementary Fig. 4).
Identification of rs2293370 as the primary functional SNP in chromosome 3q13.33. Among 
the 29 SNPs whose P values were less than 1.0 × 10−6 upon genome-wide meta-analysis, SNPs located in the 
3′-untranslated region (UTR) and synonymous substitutions were selected as potential candidates for primary 
functional variation in the chromosome 3q13.33 region (Table 2 and Fig. 2). Five of the 29 SNPs [rs57271503 
and rs3830649 in the 3′UTR of CD80, rs2305249 in exon 11 of ARHGAP31 (P567P), rs1131265 in exon 3 of 
TIMMDC1 (V146V), and rs3732421 in the 3′UTR of TMEM39A] are located in the 3′UTR or synonymous sub-
stitutions but are unrelated to their own gene expression as determined by e-QTL analysis25 (Supplementary 
Fig. 5) and thus were excluded from further analysis.
Two of the remaining 24 SNPs had RegulomeDB scores higher than 3 and these scores were supported by their 
location in DNase hyper-sensitivity clusters and the binding of transcription factor. Consequently, these two SNPs 
were selected as potential candidates26 (Table 2; rs2293370 in intron 2 of TIMMDC1 and rs56008261 in intron 8 
of ARHGAP31). Both SNPs were located in DNase I hyper-sensitivity clusters and in H3K27Ac markers in at least 
one cell type identified by the UCSC genome browser27.
We performed electrophoretic mobility shift assays (EMSAs) to evaluate the effect of candidate SNPs that 
potentially regulate the binding affinity of transcription factors. A difference in mobility shift between the major 
allele and the minor allele was detected for rs2293370 in HepG2 (Fig. 3A) and Jurkat (Supplementary Fig. 6A) 
cells. The shifted band was abrogated by incubation with a 200× concentration of a non-labeled probe (com-
petitor probe) (Fig. 3B and Supplementary Fig. 6B). In contrast, there was no difference in mobility shift for 
rs56008261 between the major allele and the minor allele (Fig. 3A and Supplementary Fig. 6A).
Figure 1. Genome-wide Manhattan plot of the GWAS meta-analysis between two data sets from the ASI and 
Japonica platforms. Negative log 10 P-values of qualified SNPs are plotted against their genomic positions. The 
genome-wide significance line (red) is shown at 7.30 (−log10 P [5e-8]). The genome-wide suggestive line (blue) 
is shown at 5 (−log10 P [1e-5]).
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Additionally, in order to deny the possibility of the existence of other variations with independent genetic 
contributions in chromosome 3q13.33, conditional logistic regression analysis was performed. When the 
rs2293370 was conditioned on, significant associations of other SNPs in chromosome 3q13.33 totally disappeared 
(Supplementary Fig. 7).
These results indicated that rs2293370 is the primary functional SNP in chromosome 3q13.33.
Molecular features of disease susceptibility influenced by rs2293370. We performed luciferase 
reporter assays in HepG2 and Jurkat cells to determine the differences in transcription efficiency between the C 
(major allele, PBC-susceptibility) and T (minor allele, PBC-protective) alleles of rs2293370. Concordant with the 
result of EMSA, the luciferase activity of cells 24 h after transfection with a reporter construct containing the C 
allele of rs2293370 was significantly higher than that of cells containing the T allele for both cell lines (Fig. 3C,D 
and Supplementary Fig. 6C).
Next, we performed in silico prediction of transcription factor binding using the TRANSFAC database28 to 
identify the transcription factor responsible for the mobility shift associated with the C allele of rs2293370. The C 
allele of rs2293370, but not the T allele, was predicted to be involved in a binding motif of Runt-related transcrip-
tion factors (Supplementary Fig. 8). Although the DMRT and Myb families also showed similar patterns, they 
are not expressed in HepG2 or Jurkat cells29. Of the Runt-related transcription factors, Runt-related transcription 
factor (RUNX1) -1, but not RUNX-2 and RUNX-3, was confirmed to be expressed in both HepG2 and Jurkat 
cells29 (Supplementary Fig. 9). Consistent with the in silico prediction of transcription factor binding, the mobility 
shift associated with the C allele of rs2293370 was reduced by pre-incubation with an anti-RUNX1 antibody prior 
to electrophoresis (Fig. 3E).
These results indicated that the PBC susceptibility allele of rs2293370 enhances transcription via binding with 
RUNX1.
The mRNA expression level of POGLUT1 is influenced by rs2293370. We used the GTEx portal 
database25 to assess the influence of rs2293370 on endogenous gene expression by comparing the expression levels 
of all genes in the human genome for the different genotypes of rs2293370 in every organ whose expression level 
of POGLUT1 was above the threshold for detection. Individuals carrying the C allele (i.e., the PBC-susceptible 
allele) of rs2293370 showed a significantly higher level of expression of POGLUT1 in several organs (Fig. 4; statis-
tical significance level: P < 0.05/47 organs = 0.00106). Other genes located in chromosome 3q13.33 (ARHGAP31, 
TMEM39A, POGLUT1, TIMMDC1, and CD80) showed no significant association between rs2293370 genotypes 
and gene expression (Supplementary Fig. 10).
Discussion
In the present study we identified chromosome 3q13.33, which includes the genes ARHGAP31, TMEM39A, 
POGLUT1, TIMMDC1, and CD80, as a PBC susceptibility locus in the Japanese population by genome-wide 
meta-analysis based on whole-genome SNP imputation analysis of two distinct data sets of Japanese PBC-GWAS. 
The role of chromosome 3q13.33 had previously been identified in European and Chinese populations. 
Consequently, rs2293370, which is located in intron 2 of TIMMDC1, was identified as the primary functional 
SNP for disease susceptibility to PBC in chromosome 3q13.33 by in silico and in vitro functional analyses. In 
addition, the disease protective allele of rs2293370 was shown to disrupt a RUNX1 binding site and was associated 
with significantly decreased POGLUT1 mRNA expression levels in tissues compared with individuals without 
this allele.
Figure 2. Regional plot of association results and recombination rates for the region surrounding POGLUT1 
(chromosome 3: 119,160,000-119,300,300). Each dot shows the P-value of each SNP after meta-analysis. The 
purple diamond represents the SNP with the minimum P-value in the region. Genetic recombination rates are 
shown with a blue line.
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The contribution of POGLUT1 to the pathogenesis of PBC has not been reported to date. Endoplasmic reticu-
lum (ER)-localized protein O-glucosyltransferase 1, which is encoded by POGLUT1, adds glucose moieties to ser-
ine residues of the epidermal growth factor (EGF)-like domains of Notch family proteins30,31. Notch signaling is 
an evolutionally conserved cascade that includes four receptors (Notch 1–4) and five ligands [Jagged 1, Jagged 2, 
Delta-like ligand 1 (DLL1), DLL3 and DLL4]. Therefore, it might be possible that genetic polymorphisms affect-
ing the expression levels of POGLUT1 influence the Notch signaling pathway by altering Notch glycosylation. 
The generation and development of diverse blood cell lineages and peripheral immune responses are regulated 
by this Notch signaling cascade, especially in hematopoiesis during T cell lineage commitment and maturation 
in the thymus, and during marginal zone B (MZB) cell development in the spleen32. Recently, dendritic cell 
(DC) homeostasis and the development of several lymphocyte subsets belonging to the innate immune system 
have been reported to be regulated by Notch32. Therefore, inappropriate immune responses against self-antigens 
could occur due to impaired regulation of Notch signaling. In experimental autoimmune encephalomyelitis 
(EAE) and non-obese diabetic (NOD) mice, which are mouse models for multiple sclerosis and type 1 diabetes 
(T1D), respectively, disease progression was impeded by the administration of blocking antibodies against Notch 
receptors or DLL432. Therefore, higher endogenous levels of POGLUT1 caused by the PBC-susceptible allele 
of rs2293370 may induce excessive Notch signaling and inappropriate immune responses against self-antigens. 
Very importantly, Notch signaling is also involved in the development or formation of intrahepatic bile ducts. 
Mutations in JAG1 or Notch2 are known causes of Alagille syndrome, an autosomal dominant disease character-
ized by congenital cholangiopathy with jaundice and bile duct paucity33–35. POGLUT1 was shown to regulate the 
number of bile ducts around portal veins in a JAG1-dependent manner using JAG1+/− and POGLUT1+/− mice36. 
These results indicate that POGLUT1 might be involved in the mechanism of bile duct loss in PBC. However, a 
limitation of this study was that endogenous POGLUT1 expression levels in PBC patients were not examined 
in this study. Additional studies are warranted to improve our understanding of the relationship between PBC 
pathogenesis and POGLUT1.
A more than 100-kb stretch of the genome is located in chromosome 3q13.33 that includes ARHGAP31, 
TMEM39A, POGLUT1, TIMMDC1, and CD80. In addition to the present study on the Japanese population, this 
rs number
SNP location 





rs57271503 119244593 imputation G A 3.48E-09 0.724 No data × CD80 3′UTR
rs9855065 119130141 imputation G A 3.57E-09 0.725 No data Δ ARHGAP31 intron 11
rs3830649 119246385 imputation G del 4.66E-09 0.727 No data × CD80 3′UTR
rs2305249 119128398 imputation G A 5.07E-09 0.727 6 × ARHGAP31 Exon 11 (P567P)
rs13092998 119245044 GWAS (Japonica) G T 5.45E-09 0.728 No data × CD80 intron 6
rs62264485 119237798 imputation C A 6.00E-09 0.728 6 Δ TIMMDC1 intron 6
rs35264490 119238753 imputation A del 6.00E-09 0.728 No data Δ TIMMDC1 intron 6
rs2293370 119219934 GWAS (ASI, Japonica) G A 6.08E-09 0.728 3a Δ TIMMDC1 intron 2
rs1463138 119128634 imputation T C 6.34E-09 0.751 6 × ARHGAP31 intron 11
rs1131265 119222456 imputation G C 6.57E-09 0.729 No data × TIMMDC1 Exon 3 (V146V)
rs1463139 119128628 imputation A G 6.70E-09 0.749 No data × ARHGAP31 intron 11
rs3732421 119150089 imputation A G 9.93E-09 0.732 5 × TMEM39A 3′UTR
rs7650774 119205050 imputation T C 1.01E-08 0.731 No data × POGLUT1 intron 6
rs12636784 119174383 imputation A G 1.27E-08 0.733 6 × TMEM39A intron 3
rs4687853 119130360 imputation A G 1.47E-08 0.754 6 × ARHGAP31 intron 11
rs9843355 119228508 imputation G A 1.79E-08 0.735 6 × TIMMDC1 intron 4
rs1530687 119114515 imputation G A 6.26E-08 0.767 5 Δ ARHGAP31 intron 8
rs9831023 119111762 GWAS (ASI, Japonica) T C 6.98E-08 0.768 5 × ARHGAP31 intron 7
rs9884090 119116150 imputation G A 9.34E-08 0.753 5 × ARHGAP31 intron 8
rs1000198 119113820 imputation A C 1.34E-07 0.771 6 × ARHGAP31 intron 8
rs11922594 119125822 imputation T C 1.50E-07 0.771 5 × ARHGAP31 intron 10
rs6773050 119123814 GWAS(ASI) C T 1.62E-07 0.774 6 × ARHGAP31 intron 10
rs12494314 119122820 imputation T C 1.90E-07 0.758 No data × ARHGAP31 intron 10
rs4279094 119114693 GWAS(ASI) A G 2.12E-07 0.774 4 × ARHGAP31 intron 8
rs9846036 119116064 imputation A C 2.12E-07 0.774 5 × ARHGAP31 intron 8
rs56008261 119114927 GWAS(Japonica) T C 2.61E-07 0.776 1b O ARHGAP31 intron 8
rs6776377 119115556 imputation T C 2.81E-07 0.776 5 × ARHGAP31 intron 8
rs6787836 119115567 imputation A G 5.85E-07 0.782 5 × ARHGAP31 intron 8
rs11715698 119118497 imputation A G 6.61E-07 0.788 5 × ARHGAP31 intron 9
Table 2. 29 SNPs associated with susceptibility to PBC in the Japanese population in chromosome 3q13.33 by 
high-density association mapping.
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locus, as represented by top-hit SNP rs2293370, has been reported as a susceptibility region to PBC in European 
and Chinese populations10,14,17. The present study identified rs2293370 as the primary functional SNP by in silico 
and in vitro functional analysis. Therefore, POGLUT1 is likely the effector gene for susceptibility to PBC in not 
only the Japanese population but also other populations. This locus has also been reported as a susceptibility 
region for celiac disease, multiple sclerosis, systemic lupus erythematosus, and vitiligo, represented by rs11712165 
in ARHGAP31, rs2293370 in TIMMDC1, and rs6804441 and rs148136154 in CD80, respectively37–40. The LDs 
were not strong between these represented tag-SNPs and rs2293370, which was identified as the primary func-
tional SNP in this study (r2 < 0.4 in 1000 genomes Asian, Supplementary Fig. 11). Regardless, rs2293370, whose 
effector gene is POGLUT1, may operate as a functional SNP in both PBC and multiple sclerosis.
The present study, compared with the GWAS in the European descent, identified four out of 30 non-HLA 
loci (IL7R, NFKB1/MANBA, chromosome 17q12-21, and chromosome 3q13.33) as susceptibility loci in the 
Japanese population. Additionally, even though the p-values were below the genome-wide significance level 
(P < 5.0 × 10−8), the direction of OR was the same between a European descent population and the Japanese 
population in MMEL1, STAT4/STAT1, IL12A, CXCR5/DDX6, and SPIB (Table 1). These loci are likely candidates 
as shared susceptibility loci for the pathogenesis of PBC between European and Japanese populations. We are cur-
rently working to clarify the shared gene profiles between different populations by conducting SNP imputation 
and subsequent meta-analysis using GWAS data from an international collaboration involving the UK, Italy, the 
USA, Canada, China and Japan.
In conclusion, genome-wide meta-analysis together with in silico/in vitro functional analyses identified the 
primary functional SNP rs2293370 and the effector gene POGLUT1. Chromosome 3q13.33 contains CD80, which 
encodes a well-known co-stimulatory signaling molecule necessary for antigen presentation from HLA class II 
Figure 3. In vitro functional analysis of each candidate variation in chromosome 3q13.33. (A) EMSA of each 
candidate primary variation using biotin-labeled probes corresponding to the major and the minor allele, and 
nuclear extracts of HepG2 cells. rs2293370 was the only SNP to show a difference in mobility shift between 
the two alleles. (B) Competitor assay, using HepG2 nuclear extracts and a 200× concentration of unlabeled 
probe corresponding to either the C (i.e., PBC susceptibility) or T alleles of rs2293370. (C) Outline of reporter 
plasmid constructs. PCR fragments of intron 2 of TIMMDC1, containing rs2293370, were sub-cloned into the 
pGL4.23 vector. (D) Transcription was measured by cellular luciferase activity, 24 h after transfection of HepG2 
cells. The luciferase activities of cells transfected with the PBC susceptibility allele (C allele) of rs2293370 were 
higher than those transfected with the T allele. Three independent experiments with triplicate measurements 
were performed for each assay, and data represent mean ± SD; *P < 0.05 (Student’s t-test). (E) Identification 
of transcription factors targeting the C allele of rs2293370. A super-shift was observed following incubation of 
HepG2 cell nuclear extracts with an anti-RUNX1 antibody. Three independent experiments were performed in 
each assay.
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to T cell receptor (TCR). CD80 had been assumed as a candidate effector gene in previous GWASs, whereas our 
approach identified POGLUT1 as the target transcript for disease susceptibility in this locus comprehensively 
without stereotypes. Of the PBC susceptibility genes identified in the Japanese population, we previously identi-
fied the primary functional SNPs of TNFSF15, PRKCB, and chromosome 17q12-21, and their effector genes16,22,41, 
as well as chromosome 3q13.33 in the present study. Similar post-GWAS approaches for susceptibility genes are 
needed to further clarify the molecular mechanisms of disease development.
Materials and Methods
Subjects. DNA samples for GWAS using the Japonica array platform were collected from 1,148 individu-
als (668 PBC cases and 480 healthy controls). The demographics of the PBC cases and controls are shown in 
Supplementary Table 1.
Written informed consent was obtained from all participants. The protocol of this study was approved by 
the committee on research ethics and genetically modified organisms of the Graduate School of Medicine, The 
University of Tokyo, by the ethics committees of Nagasaki Medical Center, and by the ethics committees of 
Tohoku Medical Megabank Organization, Tohoku University. All experiments were performed in accordance 
with relevant guidelines and regulations.
Genotyping, quality control, and genotype imputation. Genotyping was performed using the 
Japonica V1 array (1,148 Japanese individuals in the present study; Affymetrix Japan). Genotype calling was per-
formed with the apt-probeset-genotype program in Affymetrix Power Tools ver. 1.18.2 (Thermo Fisher Scientific 
Inc., Waltham, MA). Sample quality control was conducted by following the manufacturer’s recommendation 
(dish QC > 0.82 and sample call rate > 97%). Clustering of each SNP was evaluated by the Ps classification 
function in the SNPolisher package (version 1.5.2, Thermo Fisher Scientific Inc.). SNPs that were assigned “rec-
ommended” by the Ps classification function were used for downstream analyses. SNPs that satisfied the fol-
lowing criteria were used for genotype imputation: a call rate > 99.0%, a Hardy-Weinberg Equilibrium (HWE) 
p-value > 0.0001, and a minor allele frequency (MAF) > 0.5%. Pre-phasing was conducted with EAGLE v2.3.242 
Figure 4. rs2293370 genotypes are associated with differences in endogenous POGLUT1 expression 
levels. (A) The relationship between rs2293370 genotype and the endogenous expression of POGLUT1 was 
compared in all tissues registered in the GTEX database. The effect sizes of the rs2293370 minor allele (T 
allele; disease protective) in every organ are shown. Statistical significance levels before Bonferroni multiple 
comparison correction were P = 0.00116. *Pc < 0.05, **Pc < 0.005, and ***Pc < 0.0005, after Bonferroni 
multiple comparison correction. (B and C) Box plots showing the association between endogenous POGLUT1 
expression and rs2293370 genotypes in (B). Transformed Fibroblast and (C) Whole Blood.
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with default settings. Genotype imputation was conducted with IMPUTE4 v1.043 using a phased reference panel 
of 2,049 Japanese individuals from a prospective, general population cohort study performed by the Tohoku 
Medical Megabank Organization (ToMMo)44,45. These procedures were conducted using default settings. Cryptic 
relatives were excluded using PRIMUS46 with default settings. In addition, principal component analysis (PCA) 
was performed using East Asian samples from the International 1000 Genome Project (104 JPT, 103 CHB, 93 
CHS, 91 CDX, and 99 KHV samples) in addition to the case and control samples. PCA identified outliers to be 
excluded using the Smirnov-Grubbs test with a Bonferroni corrected p-value < 0.05. We had previously analyzed 
the data (2,897 Japanese individuals) using the Axiom Genome-Wide ASI 1 Array16 and re-analyzed the data 
using the above-mentioned procedures.
Association analysis and meta-analysis. Association analysis was performed with PLINK (version 1.9) 
in each dataset (i.e., 2,897 ASI array data and 1,148 Japonica array data). The following options were used for 
PLINK: a call rate > 97.0%, a HWE p-value > 0.000001, a minor allele frequency (MAF) > 0.1%, and a logistic 
regression model.
Meta-analysis was performed using PLINK with the meta-analysis option after excluding duplicates between 
the two datasets. The fixed-effects meta-analysis p-value was used.
Databases. The probability that a candidate functional variation might influence transcription regulation 
was evaluated using the RegulomeDB database (http://www.regulomedb.org/index)26 and the UCSC genome 
browser (http://genome.ucsc.edu/index.html)27. Transcription factor binding was predicted using TRANSFAC 
Professional (QIAGEN, Valencia CA; http://www.gene-regulation.com/pub/databases.html)28. Gene expression 
levels in each cell line and the correlation between the genotypes of candidate SNPs and gene expression were 
examined using GeneCards (http://www.genecards.org/) and the GTEx portal database (http://gtexportal.org/
home/), respectively25,29. P values < 0.05, after adjustment for multiple testing (Bonferroni correction), were 
regarded as statistically significant.
Electrophoretic mobility shift assay (EMSA). EMSA was performed using a LightShift Chemiluminescent 
EMSA Kit (Thermo-Fisher Scientific) and biotin-labeled double-stranded oligonucleotide probes corresponding to 
each major and minor allele (Supplementary Table 2), according to the manufacturer’s instructions. These oligonu-
cleotide probes (10 fmol/μL) and a nuclear extract (2.5 μg/mL) of HepG2 or Jurkat cells (Nuclear Extract Kit; Active 
Motif, Carlsbad, CA) were incubated together for 30 min at 25 °C.
The super-shift assay was performed by incubating the biotin-labeled probe with the nuclear extracts for 
30 min at 25 °C, before subsequently incubating these complexes with Anti-RUNX1/AML1 antibody - ChIP 
Grade (ab23980) (Abcam, Cambridge, UK) for 30 min at 25 °C.
Each assay was independently performed three times.
Luciferase reporter assay. Amplicons of part of the 2nd intron of TIMMDC1, which contain each allele of 
rs2293370, were obtained from human genomic DNA using specific PCR primers (Supplementary Table 3) and 
were then subcloned into the luciferase reporter pGL4.23 (luc2/minP) vector (Promega, Madison, WI). pGL4.23 
constructs (500 ng) of each allele and 50 ng of the pGL4.74 (hRluc/TK) vector as an internal control were trans-
fected into Jurkat and HepG2 cells using Lipofectamine 3000 (Thermo-Fisher Scientific). The Dual-Luciferase 
Reporter Assay system (Promega) was used to measure luciferase activity. Differences in relative luciferase activ-
ity were compared between the major and minor alleles of each SNP using Student’s t-test. P values < 0.05 were 
regarded as statistically significant. Each figure shows representative data from experiments performed inde-
pendently three times. The data in the figures represent the mean ± standard deviation of triplicate assays in a 
single experiment.
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